Important Information About NetCE's Response to COVID-19

Complete Your CE

Special OffersCourse ListCE RequirementsHave Questions? See Our FAQs.

Works Cited

Tuberculosis: An Update

Course #54554-

5
  • Back to Course Home
  • Participation Instructions
    • Review the course material online or in print.
    • Complete the course evaluation.
    • Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
Complete for Credit
Read Course Content

1. American Thoracic Society. News Release: New Tuberculosis Blood Test Spots Hidden Infection. Available athttp://www.washingtonpost.com/wp-dyn/content/article/2007/03/15/AR2007031500939.html. Last accessed August 31, 2022.

2. World Health Organization. Drug Resistant Tuberculosis. Available athttps://www.who.int/news/item/13-01-2012-drug-resistant-tuberculosis. Last accessed August 31, 2022.

3. Kim L, Moonan PK, Yelk Woodruff RS, Kammerer JS, Haddad MB. Epidemiology of recurrent tuberculosis in the United States, 1993–2010.Int J Tuberc Lung Dis. 2013;17(3):357-360.

4. Centers for Disease Control and Prevention. Extensively drug-resistant tuberculosis—United States, 1993–2006. MMWR. 2007;56(11):250-253.

5. Centers for Disease Control and Prevention. Extensively Drug-Resistant Tuberculosis (XDR-TB). Available at https://www.cdc.gov/TB/publications/factsheets/drtb/xdrtb.htm. Last accessed August 31, 2022.

6. Centers for Disease Control and Prevention. Interferon-Gamma Release Assays (IGRAs): Blood Tests for TB Infection. Available at https://www.cdc.gov/tb/publications/factsheets/testing/IGRA.htm. Last accessed August 31, 2022.

7. Epstein L. Tuberculosis among health care workers. Am J Nurs. 2007;107:21.

8. Centers for Disease Control and Prevention. TB Drug Resistance in the U.S. Available at https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/tb-drug-resistance-factsheet.pdf. Last accessed August 31, 2022.

9. Centers for Disease Control and Prevention. Public Health Investigation Seeks People Who May Have Been Exposed to Extensively Drug Resistant Tuberculosis (XDR-TB) Infected Person. Press Conference Transcript. Available at https://www.cdc.gov/media/transcripts/2007/t070529.htm. Last accessed August 31, 2022.

10. Centers for Disease Control and Prevention. CDC WONDER: OTIS TB Data 1993–2020 Request. Available at https://wonder.cdc.gov/TB-v2020.html. Last accessed August 31, 2022.

11. Eckler JA. Myths and facts…about tuberculosis. Nursing. 1995;25(9):17.

12. Gasner MR, Maw KL, Feldman GE, Fujiwara PI, Frieden TR. The use of legal action in New York City to ensure treatment of tuberculosis. N Engl J Med. 1999;340(5):359-366.

13. Centers for Disease Control and Prevention. Trends in tuberculosis incidence—United States, 2006. MMWR. 2007;56:245-250.

14. World Health Organization. Tuberculosis. Available at https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Last accessed August 31, 2022.

15. Petrec CA. Sputum testing for TB: getting good specimens. Am J Nurs. 1996;96(2):14.

16. Centers for Disease Control and Prevention. Update on CDC Investigation into People Potentially Exposed to Patient with Extensively Drug-Resistant TB. Press Conference Transcript. Available at https://www.cdc.gov/media/transcripts/2007/t070601.htm. Last accessed August 31, 2022.

17. Simpkins S, Hench C. "Super bugs:" emerging pathogens and multidrug-resistant organisms. NURSEweek. 1996;8(13):8-9.

18. Starke JR. Tuberculosis (Mycobacterium tuberculosis). In: Kliegman RM, Stanton BF, Schor NF, St. Geme JW III, Behrman RE (eds). Nelson Textbook of Pediatrics. 19th ed. Philadelphia, PA: WB Saunders Co.; 2011.

19. Hersh L, Salzman B, Snyderman D. Health literacy in primary care practice. Am Fam Physician. 2015;92(2):118-124.

20. Centers for Disease Control and Prevention. Tuberculosis Information for International Travelers. Available at https://www.cdc.gov/tb/publications/factsheets/general/tbtravelinfo.htm. Last accessed August 31, 2022.

21. Wang S, Carruthers B, Turner J. The influence of increasing age on susceptibility of the elderly to tuberculosis. Open Longev Sci. 2012;6:73-82.

22. Raviglione MC. Tuberculosis. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J (eds). Harrison's Principles of Internal Medicine. 19th ed. New York, NY: McGraw-Hill; 2015.

23. Centers for Disease Control and Prevention. Trends in Tuberculosis, 2020. Available at https://www.cdc.gov/tb/publications/factsheets/statistics/TBTrends.htm. Last accessed August 31, 2022.

24. Deutsch-Feldman M, Pratt RH, Price SF, Tsang CA, Self JL. Tuberculosis—United States, 2020. MMWR. 2021;70:409-414.

25. Centers for Disease Control and Prevention. Slide Set: Epidemiology of Pediatric Tuberculosis in the United States, 1993–2017. Available at https://www.cdc.gov/tb/publications/slidesets/pediatrictb/PediatricTB_SlideSet_TextOnly_2017.pdf. Last accessed August 31, 2022.

26. Soini H, Musser JM. Molecular diagnosis of mycobacteria. Clinical Chemistry. 2001;47(5):809-814.

27. Cantwell MF, Shehab ZM, Costello AM, et al. Congenital tuberculosis. N Engl J Med. 1994;330(15):1051-1054.

28. National Commission on Correctional Health Care. TB patient in compulsory detention. Correct Care. 2007;21(1):9.

29. Slovis BS, Plitman JD, Haas DW. The case against anergy testing as a routine adjunct to tuberculin skin testing. JAMA. 2000;283(15):2003-2007.

30. Nahid P, Dorman SE, Alipanah N. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016 1;63(7):e147-e195.

31. Snider GL. Tuberculosis then and now: a personal perspective on the last 50 years. Ann Intern Med. 1997;126(3):237-243.

32. Thomson PDR. Physicians' Desk Reference. 70th ed. Montvale, NJ: Thomson Healthcare; 2016.

33. York N. Management of clients with parenchymal and pleural disorders. In: Black JM, Hawks JH (eds). Medical-Surgical Nursing: Clinical Management for Positive Outcomes. 8th ed. Philadelphia, PA: WB Saunders Co.; 2008: 1597-1634.

34. Centers for Disease Control and Prevention. Core Curriculum on Tuberculosis: What the Clinician Should Know. Available at https://www.cdc.gov/tb/education/corecurr/pdf/corecurr_all.pdf. Last accessed August 31, 2022.

35. Jensen PA, Lambert LA, Iademarco MF, Ridzon R; Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR. 2005;54(RR17);1-141.

36. Alexander KA, Laver PN, Michel AL, et al. Novel Mycobacterium tuberculosis complex pathogen, M. mungi. Emerg Infect Dis. 2010;16(8):1296-1299.

37. Cousins DV, Bastida R, Cataldi A, et al. Tuberculosis in seals caused by a novel member of the Mycobacterium tuberculosis complex: Mycobacterium pinnipedii sp. nov. Int J Syst Evol Microbiol. 2003;53:1305-1314.

38. van Soolingen D, Hoogenboezem T, de Haas PEW, et al. A novel pathogenic taxon of the Mycobacterium tuberculosis complex, canetti: characterization of an exceptional isolate from Africa. Int J Syst Bacteriol. 1997;47(4):1236-1245.

39. Aranaz A, Pavlik I, Niemann S, et al. Characterization of Mycobacterium caprae isolates from Europe by mycobacterial interspersed repetitive unit genotyping. J Clin Microbiol. 2005;43(10):4984-4992.

40. Centers for Disease Control and Prevention. Anergy skin testing and preventive therapy for HIV-infected persons: revised recommendations. MMWR. 1997;46(RR15):1-10.

41. Centers for Disease Control and Prevention. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR. 2005;54(RR15):49-55.

42. LexiComp Online. Available at https://online.lexi.com. Last accessed August 25, 2022.

43. Tran JH, Montakantikul P. The safety of antituberulosis medications during breastfeeding. J Hum Lact. 1998;14(4):337-340.

44. Hoft DF, Blazevic A, Abate G, et al. A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis. 2008;198(10):1491-1501.

45. Breen RAM, Barry SM, Smith CJ, et al. The clinical application of a rapid lung-oriented TB immunoassay in individuals with possible tuberculosis. Thorax. 2008;63:67-71.

46. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64:111-115.

47. Reither K, Saathoff E, Jung J, et al. Evaluation of Diagnos TB AG, a flow-through immunoassay for rapid detection of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2010;14(2):238-240.

48. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010. MMWR. 2010;59(RR5):1-25.

49. U.S. Food and Drug Administration. Medical Devices: T-Spot.TB-P070006. Available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm?ID=320334. Last accessed August 31, 2022.

50. Van Crevel R, Hill RC. Tuberculosis. In: Cohen J, Powderly WG, Opal SM (eds). Infectious Diseases. New York, NY: Elsevier; 2016: 271-284.

51. Centers for Disease Control and Prevention. Testing for TB Infection. Available at https://www.cdc.gov/tb/topic/testing/tbtesttypes.htm. Last accessed August 31, 2022.

52. Centers for Disease Control and Prevention. Treatment Regimens for Latent TB Infection. Available at https://www.cdc.gov/tb/topic/treatment/ltbi.htm. Last accessed August 30, 2022.

53. U.S. Food and Drug Administration. FDA Approved First Drug to Treat Multi-Drug Resistant Tuberculosis. Available at https://wayback.archive-it.org/7993/20170112023916/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm. Last accessed August 31, 2022.

54. Talwar A, Tsang CA, Price SF, et al. Tuberculosis—United States, 2018. MMWR. 2019;68:257-262.

55. Centers for Disease Control and Prevention. A New Tool to Diagnose Tuberculosis: The Xpert MTB/RIF Assay. Available at https://www.cdc.gov/tb/publications/factsheets/testing/xpert_mtb-rif.htm. Last accessed August 31, 2022.

56. Parsons SD, Drewe JA, Gey van Pittius NC, Warren RM, van Helden PD. Novel cause of tuberculosis in meerkats, South Africa. Emerg Infect Dis. 2013;19(12):2004-2007.

57. Centers for Disease Control and Prevention. Deciding When to Treat Latent TB Infection. Available at https://www.cdc.gov/tb/topic/treatment/decideltbi.htm. Last accessed August 31, 2022.

58. Centers for Disease Control and Prevention. Report of Expert Consultations on Rapid Molecular Testing to Detect Drug-Resistant Tuberculosis in the United States. Available at https://www.cdc.gov/tb/topic/laboratory/rapidmoleculartesting/default.htm. Last accessed August 31, 2022.

59. USAID. The National Action Plan for Combating Multidrug-Resistant Tuberculosis. Available at https://www.usaid.gov/global-health/health-areas/tuberculosis/technical-areas/national-action-plan-combating-mdr. Last accessed August 31, 2022.

60. Centers for Disease Control and Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR. 2013;62(RR9):1-12.

61. Centers for Disease Control and Prevention. Treatment of Multidrug-Resistant Tuberculosis: Bedaquiline. Available at https://www.cdc.gov/tb/publications/factsheets/treatment/bedaquiline.htm. Last accessed August 31, 2022.

62. Centers for Disease Control and Prevention. Treatment of tuberculosis: American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR. 2003;52(RR11):1-77.

63. Los Angeles County Department of Public Health. California TB Screening Mandates by Groups and Occupations. Available at http://publichealth.lacounty.gov/tb/docs/TBScreeningMandatesSchools.pdf. Last accessed August 12, 2022.

64. U.S. Food and Drug Administration. FDA Approves New Drug for Treatment-Resistant Forms of Tuberculosis that Affects the Lungs. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs. Last accessed August 31, 2022.

65. Borisov AS, Bamrah Morris S, Njie GJ, et al. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. MMWR. 2018;67:723-726.

66. Schmitz DM, Fleissner D, Tran A. Impact of pharmacist-delivered patient education on tuberculosis drug therapy adherence. Advances in Pharmacy. 2017;1(1):Article 3.

67. Nieuwenhuizen NE, Kulkarni PS, Shaligram U, et al. The recombinant bacille Calmette-Guérin vaccine VPM1002: ready for clinical efficacy testing. Front Immunol. 2017;8:1147.

68. World Health Organization. Q&A: Investigational Vaccine Candidate M72/AS01E. Available at https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-investigational-vaccine-candidate-m72-as01e. Last accessed August 31, 2022.

69. Tait DR MB, Hatherill M, Van Der Meeren O, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med. 2019;381(25):2429-2439.

70. Filardo TD, Feng P, Pratt RH, Price SF, Self JL. Tuberculosis—United States, 2021. MMWR. 2022;71:441-446.

71. Commonwealth of Massachusetts. Nucleic Acid Amplification Testing for Early Diagnosis of Tuberculosis and Identification of Rifampin Resistance. Available at https://www.mass.gov/service-details/nucleic-acid-amplification-testing-for-early-diagnosis-of-tuberculosis-and-identification-of-rifampin-resistance. Last accessed August 31, 2022.

72. Cepheid. Xpert MTB/XDR. Available at https://www.cepheid.com/en/tests/Critical-Infectious-Diseases/Xpert-MTB-XDR. Last accessed August 31, 2022.

73. Merck Manual. CSF Findings in Meningitis. Available at https://www.merckmanuals.com/professional/multimedia/table/csf-findings-in-meningitis. Last accessed August 31, 2022.

74. Centers for Disease Control and Prevention. Provisional CDC Guidance for the Use of Pretomanid as Part of a Regimen [Bedaquiline, Pretomanid, and Linezolid (BPaL)] to Treat Drug-Resistant Tuberculosis Disease. Available at https://www.cdc.gov/tb/topic/drtb/bpal/default.htm. Last accessed August 31, 2022.

75. Carr W, Kurbatova E, Starks A, Goswami N, Allen L, Winston C. Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis—United States, 2022. MMWR. 2022;71:285-289.

76. Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR. 2020;69(1):1-11.

77. Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387:810-823.

  • Back to Course Home
  • Participation Instructions
    • Review the course material online or in print.
    • Complete the course evaluation.
    • Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
Complete for Credit
Read Course Content